General ENT News
ENT
Become a Member Today!
Email
Password
Remember me
Forgot your Password?

Invite Code?


Article ID

Home
General ENT
Messages
Conferences
Jobs
Newsletters
My Library
Topics in
ENT
        Allergy
        Basic Science/Genetics
        Clinical Pharmacology
        ENT Infectious Disease
        Economics of Medicine
        Endocrine
        Head and Neck
        Larynx/Trachea/Airway
        Nose
        Oral Cavity
        Otology/Neurotology
        Pediatric Otolaryngology
        Plastic/Reconstructive
        Popular Press
        Radiology/Diagnostics
        Salivary Glands
        Sinus
        Trauma
 
Help
Resource Center
RSS News Feeds
Send Newsletter
to a Friend
 
Sponsor
MDLinx Email Article

To email this article, enter your own "From Email" address,
the recipient's "To Email" address, and click the "Send Email" button.
You may send to up to 5 email addresses.
*From Email:  
*To Email:  
To Email:  
To Email:  
To Email:  
To Email:  
Proteomic analysis to identify cytokeratin 18 as a novel biomarker of nasopharyngeal carcinoma
Li X-M et al. - In a study to identify novel nasopharyngeal carcinoma (NPC) biomarkers, data suggest that cytokeratin 18 is a potential biomarker for differentiation and prognosis of NPC, and its dysregulation might play an important role in the pathogenesis of NPC.

Methods
  • Proteins from pooled microdissected NPC and normal nasopharyngeal epithelial tissues (NNET) were separated by 2-dimensional gel electrophoresis, and differential proteins were identified by mass spectrometry.
  • Expression of the differential protein cytokeratin 18 in the above 2 tissues as well as 4 NPC cell lines was determined by Western blotting.
  • Immunohistochemistry was performed to detect expression of cytokeratin 18 in 62 cases of primary NPC, 28 cases of NNET, and 20 cases of cervical lymph node metastases, and the correlation of its expression level with clinicopathologic features and clinical outcomes were evaluated.
  • siRNA and in vitro cell invasion assay were used to check the correlation between expression of cytokeratin 18 and invasive ability of NPC.

Results
  • 36 differential proteins between the NPC and NNET were identified.
  • Expression level of cytokeratin 18 in the 2 types of tissues was confirmed by Western blotting and related to differentiation degree and metastatic potential of the NPC cell lines.
  • Significant cytokeratin 18 down-regulation was observed in NPC vs NNET, whereas significant cytokeratin 18 up-regulation was observed in lymph node metastasis vs primary NPC.
  • Cytokeratin 18 down-regulation was significantly correlated with poor histological differentiation, whereas cytokeratin 18 up-regulation was significantly correlated with advanced clinical stage, recurrence, and regional lymph node metastasis, and distant metastasis.
  • Down-regulated cytokeratin 18 expression by siRNA significantly decreased in vitro invasive ability of 5-8F cells.
  • Survival curves showed that pts with cytokeratin 18 up-regulation had a poor prognosis.
  • Univariate analysis showed that WHO histologic type, lymph node metastasis, distant metastasis, recurrence, and cytokeratin 18 were significantly associated with prognosis of NPC.
  • Multivariate analysis confirmed that lymph node metastasis, distant metastasis, recurrence, and cytokeratin 18 were independent prognostic indicators.
[more...]

Read a Different Specialty

General ENT Articles
Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics
Pain
Pediatrics
Practice Management
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology

Profession Index

General ENT Articles
Dentist
Hospital Administrator
Nurse
    Medical Students
Nurse Practitioner
Pharma/Drug Marketer
    Pharmacist
Physician Assistants
Article Search
Keyword:
Search:
Published within:
Sort By:
Date Relevance
    
Sponsor
About MDLinx  |  Contact  |  Advertise with MDLinx  |  Site Map  |  Privacy Policy  |  Terms of Use  |  Sign Up For Newsletters  |  Recommend this Site

English |  Español |  Français |  Deutsch |  中文 |  Руccкий |  Norsk |  Nederlands |  Português |  Italiano

©1999-2009 MDLinx, Inc.